How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

5,975 results for

Digoxin

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

81. Digoxin and prognosis of heart failure in older patients with preserved ejection fraction: Importance of heart rate. Results from an observational and multicenter study. (Abstract)

Digoxin and prognosis of heart failure in older patients with preserved ejection fraction: Importance of heart rate. Results from an observational and multicenter study. The value of digoxin in heart failure (HF) remains controversial, particularly in patients with preserved ejection fraction (HFpEF). This study evaluated the 1-year risk of events after digoxin treatment for acute heart failure (AHF) in patients >70 years old with HFpEF.1833 patients were included in this analysis (mean age (...) , 82 years). The main endpoints were all-cause death and the composite of death and/or HF re-admission within 1 year. Cox regression analysis was used to evaluate the association between digoxin treatment and prognosis.401 patients received digoxin treatment; of these, 86% had atrial fibrillation. The mean baseline heart rate was 86 ± 22 bpm. At the 1-year follow-up, 375 patients (20.5%) died and 684 (37.3%) presented composite endpoints. Patients treated with digoxin showed higher rates of death (3.21

2018 European journal of internal medicine

82. Digoxin Is Associated With a Decreased Incidence of Angiodysplasia-Related Gastrointestinal Bleeding in Patients With Continuous-Flow Left Ventricular Assist Devices. Full Text available with Trip Pro

Digoxin Is Associated With a Decreased Incidence of Angiodysplasia-Related Gastrointestinal Bleeding in Patients With Continuous-Flow Left Ventricular Assist Devices. Gastrointestinal bleeding (GIB) is one of the principal adverse events affecting patients with continuous-flow left ventricular assist devices (CF-LVADs). Despite the early recognition that GIB is commonly because of gastrointestinal angiodysplasia (GIAD), the exact pathophysiology of this process remains elusive. It has been (...) postulated that the abnormal hemodynamic profile in CF-LVAD patients may activate the angiogenesis signaling cascade via the HIF (hypoxia-inducible factor)-1α/angiopoietin-2 pathway leading to formation of GIADs. Digoxin is a potent inhibitor of HIF-1α synthesis, and we hypothesized that its use reduces the incidence of GIAD and GIB in patients with CF-LVAD.Charts of all adult patients implanted with CF-LVAD between February 2006 and February 2017 were reviewed with particular emphasis on occurrence

2018 Circulation. Heart failure

83. Effect of digoxin in patients with heart failure and mid-range (borderline) left ventricular ejection fraction. Full Text available with Trip Pro

Effect of digoxin in patients with heart failure and mid-range (borderline) left ventricular ejection fraction. To evaluate the effects of digoxin in patients with the newly described phenotype of heart failure (HF) and mid-range ejection fraction (HFmrEF), attributed to mild left ventricular systolic dysfunction.We carried out a retrospective analysis of the Digitalis Investigation Group (DIG) trial which had 7788 patients available for analysis with a left ventricular ejection fraction (LVEF (...) ) ranging between 3% and 85%. We compared the effect of digoxin to placebo in three mutually exclusive groups of patients defined by LVEF category: <40% (HF with reduced LVEF, HFrEF, n = 5874), 40-49% (HFmrEF, n = 1195) and ≥50% (HF with preserved LVEF, HFpEF, n = 719). The primary outcome was the composite of cardiovascular death or HF hospitalisation. Patients with HFmrEF resembled patients with HFrEF, more than those with HFpEF, with respect to age, sex and aetiology but were more like HFpEF patients

2018 European Journal of Heart Failure Controlled trial quality: predicted high

84. Effect of Digoxin on PKM2 Binding to Pro-inflammatory Loci and Innate Immune Inflammatory Responses in the Peripheral Blood.

Effect of Digoxin on PKM2 Binding to Pro-inflammatory Loci and Innate Immune Inflammatory Responses in the Peripheral Blood. Effect of Digoxin on PKM2 Binding to Pro-inflammatory Loci and Innate Immune Inflammatory Responses in the Peripheral Blood. - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached (...) the maximum number of saved studies (100). Please remove one or more studies before adding more. Effect of Digoxin on PKM2 Binding to Pro-inflammatory Loci and Innate Immune Inflammatory Responses in the Peripheral Blood. The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our

2018 Clinical Trials

85. Phase 1 Study of Digoxin for Congenital Polycythemia Due to Up-Regulated Hypoxia Sensing

Phase 1 Study of Digoxin for Congenital Polycythemia Due to Up-Regulated Hypoxia Sensing Phase 1 Study of Digoxin for Congenital Polycythemia Due to Up-Regulated Hypoxia Sensing - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies (...) before adding more. Phase 1 Study of Digoxin for Congenital Polycythemia Due to Up-Regulated Hypoxia Sensing The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03433833 Recruitment Status : Not yet recruiting First Posted

2018 Clinical Trials

86. The effect of maraviroc on the pharmacokinetics of digoxin in healthy volunteers. (Abstract)

The effect of maraviroc on the pharmacokinetics of digoxin in healthy volunteers. 27128610 2018 09 25 2018 12 02 2160-7648 3 3 2014 05 Clinical pharmacology in drug development Clin Pharmacol Drug Dev The effect of maraviroc on the pharmacokinetics of digoxin in healthy volunteers. 202-6 10.1002/cpdd.91 Vourvahis Manoli M Pfizer Global Research and Development, New York, NY, USA. Fang Juanzhi J Pfizer Global Research and Development, Groton, CT, USA. Choo Heng Wee HW Pfizer Clinical Research (...) Unit, Singapore, Singapore. Heera Jayvant J Pfizer Global Research and Development, Groton, CT, USA. eng Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't 2014 02 06 United States Clin Pharmacol Drug Dev 101572899 2160-763X 0 ABCB1 protein, human 0 ATP Binding Cassette Transporter, Subfamily B 0 CCR5 Receptor Antagonists 0 Cyclohexanes 0 Enzyme Inhibitors 0 Triazoles 73K4184T59 Digoxin MD6P741W8A Maraviroc IM ATP Binding Cassette Transporter, Subfamily B antagonists

2018 Clinical pharmacology in drug development Controlled trial quality: uncertain

87. No Dose Adjustment is Recommended for Digoxin, Warfarin, Atorvastatin or a Combination Oral Contraceptive When Coadministered with Dulaglutide. (Abstract)

No Dose Adjustment is Recommended for Digoxin, Warfarin, Atorvastatin or a Combination Oral Contraceptive When Coadministered with Dulaglutide. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for the treatment of type 2 diabetes mellitus are known to delay gastric emptying (GE). The potential effect of the GLP-1 RA dulaglutide on the pharmacokinetics (PK) of four orally administered drugs and on the pharmacodynamic (PD) effect of warfarin was investigated.In four separate clinical (...) pharmacology studies, digoxin, warfarin, atorvastatin and Ortho-Cyclen® were orally administered to healthy subjects with and without a subcutaneous dose of dulaglutide 1.5 mg. The effect of dulaglutide coadministration was assessed based on the PK parameters of key analytes. For warfarin PD, the effect of dulaglutide on the international normalized ratio (INR) was evaluated.Areas under the concentration-time curves (AUCs) with and without dulaglutide were similar for all analytes except atorvastatin

2018 Clinical pharmacokinetics Controlled trial quality: uncertain

88. A randomised controlled proof-of-concept trial of digoxin and furosemide in adults with cutaneous warts. Full Text available with Trip Pro

A randomised controlled proof-of-concept trial of digoxin and furosemide in adults with cutaneous warts. Topical ionic contraviral therapy (ICVT) with digoxin and furosemide inhibits the potassium influx on which DNA viruses rely for replication. Therefore, ICVT was hypothesized to be a potential novel treatment for cutaneous warts.To assess the clinical efficacy, safety and tolerability of ICVT in adults with cutaneous warts. The secondary objective was to gain insight into the underlying (...) working mechanism of ICVT.Treatment with ICVT was assessed for efficacy, safety and tolerability in a single- centre, randomized, double-blind, placebo-controlled phase IIA trial. Eighty adult patients with at least two cutaneous warts (plantar or common) were randomized to one of four treatments: digoxin + furosemide (0·125%), digoxin (0·125%), furosemide (0·125%) or placebo. The gel was administered once daily for 42 consecutive days. Predefined statistical analysis was performed with a mixed-model

2018 British Journal of Dermatology Controlled trial quality: predicted high

89. Differential Effects of Digoxin on Imiquimod-Induced Psoriasis-Like Skin Inflammation on the Ear and Back Full Text available with Trip Pro

Differential Effects of Digoxin on Imiquimod-Induced Psoriasis-Like Skin Inflammation on the Ear and Back 30065596 2018 11 14 1013-9087 30 4 2018 Aug Annals of dermatology Ann Dermatol Differential Effects of Digoxin on Imiquimod-Induced Psoriasis-Like Skin Inflammation on the Ear and Back. 485-488 10.5021/ad.2018.30.4.485 Madsen Marie M https://orcid.org/0000-0001-6579-9376 Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark. Pedersen Tanja Xenia TX Department

2018 Annals of dermatology

90. PBPK Models for CYP3A4 and P‐gp DDI Prediction: A Modeling Network of Rifampicin, Itraconazole, Clarithromycin, Midazolam, Alfentanil, and Digoxin Full Text available with Trip Pro

PBPK Models for CYP3A4 and P‐gp DDI Prediction: A Modeling Network of Rifampicin, Itraconazole, Clarithromycin, Midazolam, Alfentanil, and Digoxin According to current US Food and Drug Administration (FDA) and European Medicines Agency (EMA) guidance documents, physiologically based pharmacokinetic (PBPK) modeling is a powerful tool to explore and quantitatively predict drug-drug interactions (DDIs) and may offer an alternative to dedicated clinical trials. This study provides whole-body PBPK (...) models of rifampicin, itraconazole, clarithromycin, midazolam, alfentanil, and digoxin within the Open Systems Pharmacology (OSP) Suite. All models were built independently, coupled using reported interaction parameters, and mutually evaluated to verify their predictive performance by simulating published clinical DDI studies. In total, 112 studies were used for model development and 57 studies for DDI prediction. 93% of the predicted area under the plasma concentration-time curve (AUC) ratios and 94

2018 CPT: pharmacometrics & systems pharmacology

91. Digoxin, Octreotide and Omega 3 fatty acid to prevent bleeding in post-LVAD patients: A network meta-analysis

Digoxin, Octreotide and Omega 3 fatty acid to prevent bleeding in post-LVAD patients: A network meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files (...) are not reported or unclear, we will attempt to contact authors by e-mail (max. 2 attempts). In case an outcome is measured at multiple time points, data from the time point where efficacy is highest will be included. ">Methods for data extraction Example: Experimental groups, control group(s) and number of animals per group. ">Data to be extracted: study design Example: Species, sex, weight, age, co‐morbidity, anaesthetic agent used, method of induction of cardiac ischemia, duration of ischemia and duration

2020 PROSPERO

92. Pharmacological treatment of cardiac glycoside poisoning Full Text available with Trip Pro

Pharmacological treatment of cardiac glycoside poisoning Cardiac glycosides are an important cause of poisoning, reflecting their widespread clinical usage and presence in natural sources. Poisoning can manifest as varying degrees of toxicity. Predominant clinical features include gastrointestinal signs, bradycardia and heart block. Death occurs from ventricular fibrillation or tachycardia. A wide range of treatments have been used, the more common including activated charcoal, atropine, β (...) -adrenoceptor agonists, temporary pacing, anti-digoxin Fab and magnesium, and more novel agents include fructose-1,6-diphosphate (clinical trial in progress) and anticalin. However, even in the case of those treatments that have been in use for decades, there is debate regarding their efficacy, the indications and dosage that optimizes outcomes. This contributes to variability in use across the world. Another factor influencing usage is access. Barriers to access include the requirement for transfer

2015 British journal of clinical pharmacology

93. Digoxin Immune Fab Treatment of Preeclampsia in Women with Endogenous Digitalis-like Factor: A Secondary Analysis of the DEEP Trial. (Abstract)

Digoxin Immune Fab Treatment of Preeclampsia in Women with Endogenous Digitalis-like Factor: A Secondary Analysis of the DEEP Trial. Endogenous digitalis-like factors (EDLFs) are elevated in women with preeclampsia, and the use of an anti-digoxin antibody Fab (DIF) in women with preeclampsia who were remote from term reduced maternal blood pressure and preserved renal function. The objective was to determine whether DIF treatment in women with severe preeclampsia in association with positive

2013 American journal of obstetrics and gynecology Controlled trial quality: predicted high

94. Cohort study: Digoxin initiation is associated with lower risk of all-cause readmission after hospitalisation for heart failure

Cohort study: Digoxin initiation is associated with lower risk of all-cause readmission after hospitalisation for heart failure Digoxin initiation is associated with lower risk of all-cause readmission after hospitalisation for heart failure | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using (...) your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Digoxin initiation is associated with lower risk of all-cause readmission after hospitalisation for heart failure Article Text Prognosis Cohort

2014 Evidence-Based Medicine

95. Myocardial digoxin uptake: dissociation between digitalis-induced inotropism and myocardial loss of potassium. Full Text available with Trip Pro

Myocardial digoxin uptake: dissociation between digitalis-induced inotropism and myocardial loss of potassium. The time course of myocardial uptake of digoxin, of increase in inotropic effect and of changes in myocardial potassium content were studied following a single intravenous dose of digoxin. Nineteen dogs with intact circulation were investigated by the use of a biopsy technique which allowed samplings before and 10, 30, 60, and 90 min after administration of digoxin. The myocardial (...) significant fall in the myocardial potassium content probably reflects ATPase inhibition. The temporal dissociation between the early onset of the positive inotropic effect and the delayed inhibition of membrane Na+-K+ ATPase indicates that inotropism of digitalis glycosides is not mediated by the same binding site as that responsible for inhibition of Na+-K+ ATPase.

1976 British journal of pharmacology

96. Cat assay for the emetic action of digitalis and related glycosides (digitoxin, digoxin, lanatoside C, ouabain and calactin) Full Text available with Trip Pro

Cat assay for the emetic action of digitalis and related glycosides (digitoxin, digoxin, lanatoside C, ouabain and calactin) 1. A titration assay with two end points is described for comparison of the emetic and lethal potencies of digitalis-like drugs.2. A drug was infused at constant rate to a conscious, unrestrained cat, through an indwelling venous cannula. At the moment of vomiting the cat was rapidly anaesthetized and infusion continued at the same rate until the moment of cardiac arrest (...) .3. With very slow and very fast infusions, the emetic and lethal doses tended to rise. In the range between these extremes (which varied from drug to drug) they were independent of time.4. The observations could be accounted for by analogue computation, assuming that the drugs entered an initial pool and were distributed at finite rates to receptors in the CNS (vomiting centre) and heart.5. Half times of metabolic loss derived from this computation for digitoxin, digoxin and ouabain (17, 9.9

1971 British journal of pharmacology

97. Digoxin Therapy of Fetal Superior Ventricular Tachycardia: Are Digoxin Serum Levels Reliable? Full Text available with Trip Pro

tachycardia developed chest pain, shortness of breath, and bigeminy on electrocardiogram secondary to digoxin toxicity despite subtherapeutic serum drug levels. She required supportive care with repletion of corresponding electrolyte abnormalities. After resolution of cardiac manifestations of digoxin toxicity, the patient was discharged home. The newborn was discharged at day 9 of life on maintenance amiodarone.We describe an interesting case of digoxin toxicity with cardiac manifestations of digoxin (...) Digoxin Therapy of Fetal Superior Ventricular Tachycardia: Are Digoxin Serum Levels Reliable? Despite its seldom occurrence, fetal tachycardia can lead to poor fetal outcomes including hydrops and fetal death. Management can be challenging and result in maternal adverse effects secondary to high serum drug levels required to achieve effective transplacental antiarrhythmic drug therapy.A 33-year-old woman at 33 weeks of gestation with a diagnosis of a fetal sustained superior ventricular

2016 AJP Reports

98. Pharmacokinetic Evaluation of a Drug Transporter Cocktail Consisting of Digoxin, Furosemide, Metformin, and Rosuvastatin. Full Text available with Trip Pro

Pharmacokinetic Evaluation of a Drug Transporter Cocktail Consisting of Digoxin, Furosemide, Metformin, and Rosuvastatin. This article reports the clinical investigation of a probe drug cocktail containing substrates of key drug transporters. Single oral doses of 0.25 mg digoxin (P-gp), 5 mg furosemide (OAT1 and OAT3), 500 mg metformin (OCT2, MATE1, and MATE2-K), and 10 mg rosuvastatin (OATP1B1, OATP1B3, and BCRP) were administered separately or as a cocktail in a randomized six-period (...) crossover trial in 24 healthy male volunteers. As a cocktail, relative bioavailabilities of digoxin and metformin and furosemide AUC0-tz were similar to separate dosing. However, when administered as a cocktail the Cmax of furosemide was 19.1% lower and the Cmax and AUC0-tz of rosuvastatin were 38.6% and 43.4% higher, respectively. In addition, the effects of increased doses of metformin or furosemide on the cocktail were investigated in 11 and 12 subjects, respectively. The cocktail explored

2017 Clinical pharmacology and therapeutics Controlled trial quality: uncertain

99. Digoxin enhances radiation response in radioresistant A549 cells by reducing protein phosphatase 2A Full Text available with Trip Pro

Digoxin enhances radiation response in radioresistant A549 cells by reducing protein phosphatase 2A Protein phosphatase 2A (PP2A) is a ubiquitous multifunctional enzyme usually known as a tumor suppressor. Recent studies have reported that although inhibition of PP2A leads to acceleration of cell growth, it also induces damaged cells to pass through the cell cycle and renders them sensitive to radiotherapy. Here, we investigated the radiosensitizing effects of digoxin as a PP2A inhibitor in two (...) non-small-cell lung cancer (NSCLC) cell types (H460 and A549) with differential sensitivity to radiation. Digoxin inhibited the proliferation of H460 and A549 cells in a dose-dependent fashion and was especially effective on radioresistant A549 cells. Interestingly, the radiosensitizing effect of digoxin was only present in the radioresistant A549 cells and xenografts. The combination of digoxin and ionizing radiation (IR) significantly reduced clonogenic survival and xenograft tumor growth (P

2017 Bioscience reports

100. Appropriateness of digoxin measurement in hospitalized patients Full Text available with Trip Pro

Appropriateness of digoxin measurement in hospitalized patients Measurement of serum digoxin concentrations before steady-state is reached results in a falsely low concentration, and may affect treatment safety. We evaluated the proportion of serum digoxin measurements performed before steady-state is reached and the reasons for inappropriate sampling in hospitalized patients.Electronic medical records of patients hospitalized between January 2011 and December 2015 treated with oral digoxin (...) , that had more than one digoxin measurement were included. Serum digoxin measurements performed before achievement of pharmacological steady state were considered as inappropriate. The chi-square and chi-square for trend tests were used to analyse the relationship between inappropriate measurements and age, gender, diagnosis, inpatient service, serum digoxin, potassium and creatinine concentrations.We evaluated 2065 hospital admissions for 1621 patients and 11,407 digoxin measurements. The time between

2017 Biochemia medica

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>